Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts
Class III · Low risk Terminated Initiated Apr 7, 2015 (12 years ago)

Olanzapine

Class III — Low risk. Unlikely to cause harm, but violates FDA regulations.

Why it was recalled

Subpotent drug

Cause type: Wrong potency / content

Sub- or super-potent product, or a failed content-uniformity / assay test. You may receive too little or too much active ingredient - a direct dosing risk. All wrong potency / content recalls.

What was recalled

Olanzapine, Orally Disintegrating Tablets, 20 mg, 30-count bottle, Rx only, Manufactured by Apotex Inc. Toronto, Ontario Canada, M9L 1T9

Drug: Olanzapine

Recalling firm
Apotex Inc.
Origin
N/A, Canada
Initiated by
Voluntary: Firm initiated
FDA recall number
D-1081-2015 · FDA notice

Low risk, still worth a check. Class III means the product is unlikely to cause harm but breaks an FDA rule (often labeling). If your lot matches, your pharmacy will normally swap it; there is no need for alarm. This recall is now terminated, which means the firm has finished removing the affected product; anything on pharmacy shelves today should be unaffected.

Other Olanzapine recalls

See all
Class III · Low risk

Olanzapine Tablets

Failed Impurities/Degradation Specifications:Organic and unspecified impurities above specification.

Ongoing Impurity / degradation Macleods Pharmaceuticals Limited NDC 33342-068-07 D-0867-2026

Other recalls by Apotex Inc.

All 2015 recalls
Class II · Moderate risk

Paxil CR

Failed Dissolution Specifications; product failed to meet 24-month stability testing acceptance criteria

Ongoing Dissolution failure Apotex Corp. NDC 60505-4379-3 D-0804-2026
Class II · Moderate risk

Desmopressin Nasal Spray

Defective container: defect in a batch of bottle caps, specifically involving dislodged or missing cap liners.

Ongoing Packaging defect Apotex Corp. NDC 60505-0815-0 D-0510-2026